>NOVC – If you think Doxapin from Somaxon is a doomed product because of generics, how about a low dose ambien for middle of the night dosing when you can split a generic?<
Agreed—hopeless product from a commercial standpoint. Reminds me of NTMD’s BiDil.
<font size=2><font color=red>“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
NOVC was off 16% today on an announcement that the company has no interest in developing Asentar for HRPC. This is bizarre insofar as Asentar was already dead as a doorknob.
NOVC is being acquired by a private company in a reverse merger (#msg-31869987).
Market Data 
Markets 
AI
